Autoreactivity of Broadly Neutralizing Influenza Human Antibodies to Human Tissues and Human Proteins.
Antibodies, Monoclonal
/ immunology
Antibodies, Neutralizing
/ immunology
Antibodies, Viral
/ immunology
Autoantibodies
/ immunology
Broadly Neutralizing Antibodies
/ immunology
HIV Antibodies
/ immunology
HIV-1
/ immunology
Hemagglutinin Glycoproteins, Influenza Virus
/ immunology
Humans
Immunoglobulin Heavy Chains
/ immunology
Influenza Vaccines
/ adverse effects
Influenza, Human
/ prevention & control
Ribonucleoproteins, Small Nuclear
/ immunology
Single-Chain Antibodies
/ immunology
antibody affinity
autoreactivity
bNAbs
head
hemagglutinin
influenza
polyreactivity
stem
universal influenza
vaccine
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
08 10 2020
08 10 2020
Historique:
received:
21
08
2020
revised:
24
09
2020
accepted:
26
09
2020
entrez:
14
10
2020
pubmed:
15
10
2020
medline:
24
2
2021
Statut:
epublish
Résumé
Broadly neutralizing monoclonal antibodies (bNAbs) against conserved domains in the influenza hemagglutinin are in clinical trials. Several next generation influenza vaccines designed to elicit such bNAbs are also in clinical development. One of the common features of the isolated bNAbs is the use of restricted IgV
Identifiants
pubmed: 33049994
pii: v12101140
doi: 10.3390/v12101140
pmc: PMC7600923
pii:
doi:
Substances chimiques
4E10 monoclonal antibody
0
Antibodies, Monoclonal
0
Antibodies, Neutralizing
0
Antibodies, Viral
0
Autoantibodies
0
Broadly Neutralizing Antibodies
0
EDC3 protein, human
0
HIV Antibodies
0
Hemagglutinin Glycoproteins, Influenza Virus
0
Immunoglobulin Heavy Chains
0
Influenza Vaccines
0
Ribonucleoproteins, Small Nuclear
0
Single-Chain Antibodies
0
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Références
Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):264-9
pubmed: 23175789
PLoS One. 2008;3(12):e3942
pubmed: 19079604
Sci Rep. 2019 Mar 5;9(1):3492
pubmed: 30837606
Immunity. 2018 Jan 16;48(1):133-146.e6
pubmed: 29287996
Sci Transl Med. 2015 Dec 2;7(316):316ra192
pubmed: 26631631
J Virol. 2015 Jan;89(1):784-98
pubmed: 25355869
Immunity. 2019 Oct 15;51(4):735-749.e8
pubmed: 31563464
Mol Cell Biol. 2008 Oct;28(19):5965-76
pubmed: 18678652
J Exp Med. 2013 Feb 11;210(2):241-56
pubmed: 23359068
Vaccines (Basel). 2018 Apr 27;6(2):
pubmed: 29702547
J Infect Dis. 1997 Nov;176(5):1215-24
pubmed: 9359721
Science. 2009 Apr 10;324(5924):246-51
pubmed: 19251591
Lancet Infect Dis. 2020 Jan;20(1):80-91
pubmed: 31630990
Immunol Rev. 2015 Nov;268(1):328-39
pubmed: 26497531
Vaccine. 2016 Oct 26;34(45):5442-5448
pubmed: 27622299
Science. 2011 Aug 12;333(6044):843-50
pubmed: 21737702
Expert Rev Vaccines. 2017 May;16(5):503-513
pubmed: 28277797
Nature. 2012 Sep 27;489(7417):566-70
pubmed: 22932267
Nat Protoc. 2009;4(3):372-84
pubmed: 19247287